Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.47 |
| ▸ | HTT | P42858 | 4/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833863 | 0.85 | METAP2 (0.48) | KDM4EALDH1A1SIRT2HTTMAPK1 | |
| SCHEMBL6709145 | 0.85 | SIRT2 (0.56) | MAPTKDM4EALDH1A1HPGDSIRT2 | |
| SCHEMBL6710371 | 0.84 | MAPT (0.46) | MAPTKDM4EALDH1A1HPGDSIRT2 | |
| SCHEMBL6708825 | 0.79 | SIRT2 (0.38) | MAPTKDM4ESIRT2HTTMAPK1 | |
| SCHEMBL15838803 | 0.74 | SIRT2 (0.73) | MAPTKDM4EALDH1A1HPGDSIRT2 | |
| SCHEMBL6710402 | 0.73 | ALAD (0.49) | KDM4ESIRT2HTTMAPK1MEN1 | |
| SCHEMBL15953505 | 0.72 | SIRT2 (0.74) | MAPTKDM4EALDH1A1HPGDSIRT2 | |
| SCHEMBL6351360 | 0.69 | METAP2 (0.55) | MAPTKDM4ESIRT2HTTMAPK1 | |
| SCHEMBL6833131 | 0.69 | METAP2 (0.47) | MAPTKDM4ESIRT2MEN1KMT2A | |
| SCHEMBL6819031 | 0.69 | METAP2 (0.46) | MAPTKDM4ESIRT2HTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | MAPT 4754/4885KDM4E 1582/4885ALDH1A1 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.